CONSUNPHARMA：ANNUALRESULTSANNOUNCEMENTFORTHEYEARENDED31DECEMBER2025.pdf

1、1Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in relia

2、nce upon the whole or any part of the contents of this announcement.(Incorporated in the Cayman Islands with limited liability)(Stock Code:1681)ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED 31 DECEMBER 2025FINANCIAL HIGHLIGHTS Revenue for the year ended 31 December 2025 amounted to RMB3,417,355,000,

3、representing an increase of approximately 15.2%as compared with the year ended 31 December 2024.Profit attributable to equity shareholders of the Company for the year ended 31 December 2025 amounted to RMB1,078,067,000,representing an increase of approximately 18.4%as compared with the year ended 31

4、 December 2024.Basic and diluted earnings per share for the year ended 31 December 2025 amounted to approximately RMB1.27 and RMB1.26 respectively,representing increases of approximately 14.4%and 15.6%respectively as compared with the year ended 31 December 2024.The Board proposed to declare a final

5、 dividend of HKD0.40 per share for the year ended 31 December 2025.ANNUAL RESULTSThe board(the“Board”)of directors(the“Directors”)of Consun Pharmaceutical Group Limited(the“Company”)is pleased to announce the consolidated financial results of the Company and its subsidiaries(collectively the“Group”,

6、“Consun”,“Consun Pharmaceutical”or“Consun Pharmaceutical Group”)for the year ended 31 December 2025(the“Reporting Period”),together with the comparative figures of 2024 as follows:2CONSOLIDATED STATEMENT OF PROFIT OR LOSSfor the year ended 31 December 2025(Expressed in Renminbi)Note20252024RMB000RMB